Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy’s LIGHT system has “fast head start” on changing cancer treatment market, says broker goetzpartners

The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
Proton Therapy sign
The broker says the LIGHT system is “faster and less complicated" than cyclotron technology

Advanced Oncotherapy PLC (LON:AVO), which is developing a breakthrough new proton therapy system for cancer sufferers, could have a “fast head-start” in the race to replace other forms of treatment in the market, according to analysts at broker goetzpartners.

In a note to clients, the broker said that the company’s proton beam treatment system, known as Linac Image Guided Hadron Technology (LIGHT), could help it take “the entire growth” from its cyclotron competitors, a technology that will become obsolete by the end of 2023.

Cyclotron technology involves lengthy and complicated building preparation, with heavy cyclotrons and large concrete bunkers make the installation a major building project, which is, regardless of pricing, often a big hurdle.

However, the broker says the LIGHT system, which is “faster and less complicated combined with a cheaper production process”, could give the company a step up against both cyclotrons and more conventional LINAC (linear accelerator) systems.

The proton therapy industry, in which AVO operates, offers “significant structural growth”, goetz said, with its own numbers forecasting a US$8bn market by the end of 2030.

LIGHT tech backed by world-leading physicists

AVO’s beam technology is currently being worked on by the team at ADAM, a spin-off from renowned Swiss physics lab CERN, which includes some of the world leading physicists.

The firm recently announced that it had successfully integrated the four sections of its LIGHT proton accelerator, the proton source, the Radiofrequency Quadrupole (RFQ), four Side Coupled Drift Tube Linacs (SCDTLs), and two high-energy accelerating structures, the Coupled Cavity Linacs (CCLs), at the lab and had achieved an energy of 52 mega-electron volts (MeV), double the amount needed to treat superficial cancer tumours.

READ: Advanced Oncotherapy rockets as it improves performance of LIGHT cancer treatment system

However, the company isn’t stopping and is aiming to add 13 more CCL modules which would increase the energy level to 230MeV, the level required to treat deep-seated tumours.

goetzpartners expects the company to achieve this energy level in 2019, adding that they saw “limited” risks to the set up of the company’s LIGHT system for its first customer at a clinic in Harley Street, the renowned private medical district in London.

First player in ‘holistic’ oncology process

AVO’s partnership with Swedish radiotherapy software firm, RaySearch, also gives it a potential first-mover advantage in developing “a fully integrated and holistic oncology treatment process”, says goetz.

The broker says that the combination of the LIGHT system and RaySearch’s treatment planning and oncology information systems would go “far beyond an optimal use of proton therapy systems”.

goetzpartners has Advanced Oncotherapy pegged with an ‘Outperform’ rating and a price target of 155p, a premium of over 255% on its current share price of 43.5p.

With a current market cap of £55.9mln, the broker is targeting a potential value of around £143mln.

View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

Related Articles

test tubes
May 07 2019
Here we take a closer look at Arix Biosciences PLC (LON:ARIX), a listed venture capital company that doesn’t appear to be receiving the recognition it deserves
cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers
microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use